Does the type of statin matter for men’s sexual health? Mendelian randomization studies suggest that lipophilic statins may have a higher long-term genetic risk for erectile dysfunction, whereas the effects of rosuvastatin appear to be neutral.
Study: Causal relationship between statin use and erectile dysfunction: A two-sample Mendelian randomized study. Image credit: michaelheim/Shutterstock.com
Certain cholesterol-lowering statins, particularly atorvastatin and simvastatin, may increase the long-term risk of erectile dysfunction, according to genetic evidence from a Mendelian randomized study published in 2006. sexual medicine.
Research on statins and erectile dysfunction
Erectile dysfunction is a major public health crisis, affecting the quality of life of more than 300 million men worldwide. Vascular disorders such as high blood pressure and high cholesterol are one of the major risk factors for erectile dysfunction. These vascular conditions interfere with normal blood flow to the penis, causing erectile dysfunction.
Statins, a group of cholesterol-lowering drugs, are primarily used to treat conditions such as dyslipidemia and cardiovascular disease. However, the effect of statins on erectile dysfunction remains a highly controversial issue in medicine.
Some studies suggest that statins protect against erectile dysfunction and improve sexual health in men. These benefits may be related to statin-mediated increases in nitric oxide bioavailability and inhibition of signaling pathways that control cytoskeletal organization, cell migration, and contraction. These mechanisms improve vascular health and increase blood flow to the penis, which is necessary for erection.
On the other hand, some studies have linked statin use to decreased erectile ability. The lowering of cholesterol levels by statins may explain these adverse effects. Cholesterol is required for the biosynthesis of testosterone and other male hormones. Therefore, lower cholesterol levels are associated with lower blood levels of these hormones, which can negatively impact sexual desire and the ability to get an erection.
Given these conflicting findings, researchers from the Department of Urology, Sixth Hospital in Wuhan, China, used Mendelian randomization (MR) to investigate whether statin use was causally related to erectile dysfunction. They analyzed large-scale genome-wide association study (GWAS) data from UK Biobank and FinGen.
Mendelian randomization uses naturally occurring genetic variation associated with exposure (in this case, statin use) to simulate a randomized clinical trial. Because these genetic variations are inherited randomly at conception, this approach reduces the influence of environmental confounders and helps reverse causality, providing stronger evidence of causality than traditional observational studies.
Researchers used genetic variation associated with statin use overall and the commonly prescribed statins atorvastatin, simvastatin, and rosuvastatin to assess whether genetically predicted statin use was causally associated with the risk of erectile dysfunction.
Atorvastatin and simvastatin show higher genetic risk
Mendelian randomization analysis found genetic evidence that overall statin use is associated with increased risk of erectile dysfunction. When researchers looked at individual statins, they found that this association was driven by the lipophilic statins atorvastatin and simvastatin, both of which showed significant associations with increased risk of erectile dysfunction. In contrast, rosuvastatin, a hydrophilic statin, showed no evidence of a causal relationship.
Additional analyzes strengthened our confidence in these findings. Directionality tests confirmed that the observed association continued from statin use to erectile dysfunction rather than vice versa, while leave-one-out analyzes confirmed that the results were not unduly influenced by a single genetic variation.
Statin chemistry may explain different risks of erectile dysfunction
To explain why different types of statins have different effects, researchers point to the different chemical properties of statins. Lipophilic statins, such as atorvastatin and simvastatin, can more easily cross the blood-testis barrier and may interfere with testosterone production by suppressing local mevalonate metabolism. Although this mechanism has not yet been experimentally confirmed, researchers suggest that it may help explain why these statins are associated with a higher risk of erectile dysfunction.
By comparison, rosuvastatin is a hydrophilic statin with higher selectivity for the liver and a more limited ability to cross the blood-testis barrier. This difference may explain why this study found no evidence of a causal relationship between rosuvastatin use and erectile dysfunction.
The researchers also propose that differences in cholesterol-lowering effects may play a role. Because cholesterol is the starting material for testosterone and other steroid hormones, statins that produce significant reductions in circulating cholesterol may have less substrate available for hormone production, which may contribute to the differences in erectile dysfunction risk observed between statin types.
One finding that the authors urge readers to interpret with caution is the very strong association observed with atorvastatin. The researchers explain that this estimate reflects the theoretical cumulative effect of lifelong genetic exposure on low cholesterol biosynthesis, rather than the risks faced by patients taking atorvastatin over a relatively short period of time in routine clinical practice. Therefore, this result should be viewed as genetic evidence supporting a biological link between specific statins and erectile dysfunction, rather than as a direct measure of real-world clinical risk that would change current prescribing practices or raise unnecessary concerns.
Researchers call for cautious clinical interpretation
Overall, the findings of this study inform clinicians to regularly monitor the sexual health of patients receiving statin therapy. Prescribing rosuvastatin may be a beneficial strategy for patients experiencing erectile dysfunction.
The Mendelian randomization design used in this study represents a lifetime of exposure, limiting the evaluation of specific effects of dosage or treatment duration. The authors also note that they were unable to perform analyzes according to subtypes of erectile dysfunction or important clinical characteristics such as age, hypertension, diabetes, and metabolic syndrome, limiting their ability to provide more individualized treatment guidance. The study population was limited to European ancestry, which may limit the generalizability of the study results to other ethnic groups.
Future studies should consider these limitations and include the full range of statin drugs, such as lovastatin, pravastatin, and fluvastatin, for a more definitive risk interpretation.
Download your PDF copy now.
